FDA Warns Against Compounded Moxifloxacin Injections
FDA received case reports of TASS (Toxic Anterior Segment Syndrome) following intraocular administration of compounded drugs using moxifloxacin as a bulk drug substance, as well as reports associated with the intraocular administration of repackaged and/or diluted FDA-approved moxifloxacin drugs.
Dr. David Hussong explains the FDA’s recent alert to health care professionals of risks associated with intraocular use of compounded moxifloxacin.
Learn more about this on the FDA website through the link below:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-associated-intraocular-use-compounded-moxifloxacin
Eagle is an FDA and DEA registered, A2LA ISO 17025 accredited laboratory providing analytical and microbiological testing services along with expert consulting services to 503A compounding pharmacies, 503B outsourcing facilities, and pharmaceutical companies.
Latest posts by Eagle Analytical (see all)
- Celebrate Safely During This Holiday Season - November 25, 2020
- Happy Thanksgiving – Our Holiday Schedule - November 19, 2020
- FDA Finalizes Insanitary Conditions Guidance for Compounding Facilities - November 6, 2020
Please post this video or transcript in the requests for comments of the FDA’s Federal Register docket. This is absolutely sound scientific information that refutes current FDA stance on using the topical drops for intraocular injections. It is putting patients in harms way.